Home | Health | Blood Streams
Immunicon Corporation (NASDAQ-GM:IMMC) will make an oral presentation at the annual meeting of the American Association of Blood Banks at 4:30 p.m. ET on October 23, 2006, at the Miami Beach Convention Center in Miami Beach, Florida. Dania Yaskanin, Ph.D., Senior Scientist of Immunicon, will present, “Enumeration of Residual Leukocytes in Leukodepleted Blood Products with a Simple Fluorescence Imaging System.” The talk will describe the Company’s EasyCount™ IMS System and EasyCount™ Leukodepletion Kit, the first immunomagnetic application designed for this proprietary system. Currently, blood banks filter units of blood to remove white blood cells from the product (called leukodepletion or leukoreduction) before it is sent to hospitals for blood infusions. Donor white blood cells can cause adverse events ranging from a fever reaction in a relatively healthy patient to life threatening reactions in patients with weak immune systems, due to transplant, cancer or HIV disease. A fraction of all of the units that are collected and leukoreduced must be quality control tested to ensure that the number of residual white blood cells meets FDA requirements. Many blood banks use a manual QC method that involves counting cells under a microscope in a special chamber. This process is time and labor intensive. The EasyCount™ IMS System automates this test, removes the subjectivity associated with the manual method and improves the efficiency of the QC process. Dr. Yaskanin will show preliminary performance data generated with prototype instruments and reagents in her presentation. Product development is ongoing. About Immunicon Corporation Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management. Immunicon has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. www.immunicon.com. Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as “hope,” “may,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “assume,” “will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to the anticipated clinical utility of Immunicon’s products and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon’s ability to obtain licenses from third parties to commercialize products; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors’ products; protection of Immunicon’s intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services. “Immunicon” and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. EasyCount™ is a trademark of Immunivest Corporation, a wholly owned subsidiary of Immunicon Corporation. ALL RIGHTS RESERVED.
Article Source: http://www.content.onlypunjab.com
For more information about the AABB annual meeting, please visit www.aabb.org.
Please Rate this Article
5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
